<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font6" size="9" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font7" size="9" family="GillSans,Italic" color="#000000"/>
	<fontspec id="font8" size="10" family="Symbol" color="#000000"/>
	<fontspec id="font9" size="7" family="Giovanni-Book" color="#000000"/>
<text top="41" left="55" width="162" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Genetic Vaccines and Therapy 2007, 5 :5<i>Genetic Vaccines and Therapy</i></text>
<text top="41" left="394" width="160" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.gvt-journal.com/content/5/1/5</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t3" reading_order_no="105" segment_no="15" tag_type="text">Page 4 of 9<b>5</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="106" segment_no="16" tag_type="text">(page number not for citation purposes)</text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="text">hairpin to form an intracellular siRNA. To date, small</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="text">interfering RNAs have been used in vitro to target viral</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="4" segment_no="2" tag_type="text">genes like tat and rev [31] and cellular genes like CCR5<i>(page number not for citation purposes)</i></text>
<text top="122" left="55" width="97" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">[32] with great success.</text>
<text top="146" left="55" width="170" height="9" font="font6" id="p1_t9" reading_order_no="6" segment_no="4" tag_type="title">Protein and nucleic acid-based strategies</text>
<text top="157" left="55" width="34" height="9" font="font7" id="p1_t10" reading_order_no="7" segment_no="5" tag_type="title">Aptamers<i>in vitro </i></text>
<text top="169" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="6" tag_type="text">In general, aptamers refer to short RNA, DNA, or protein</text>
<text top="181" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="6" tag_type="text">sequences that bind a variety of specific target molecules,</text>
<text top="192" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="6" tag_type="text">including nucleic acids and proteins. Small RNA aptamers<i>tat </i></text>
<text top="204" left="55" width="242" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="6" tag_type="text">have shown success in vitro against HIV Rev [33,34] and</text>
<text top="216" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="6" tag_type="text">reverse transcriptase [35]. Aptamers can be used in con-<i>rev </i></text>
<text top="228" left="55" width="227" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="6" tag_type="text">junction with other therapies, such as ribozymes [35].<a href="">[31] and cellular</a> genes like CCR5</text>
<text top="251" left="55" width="238" height="9" font="font6" id="p1_t17" reading_order_no="14" segment_no="8" tag_type="title">Application of bench-side treatment strategies to bedside<a href="">[32] with</a> great success.</text>
<text top="263" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="9" tag_type="text">The early success of in vitro studies paved the way for clin-<i><b>Protein and nucleic acid-based strategies</b></i></text>
<text top="275" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="9" tag_type="text">ical trials. All the above-mentioned strategies for gene<i>Aptamers</i></text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="9" tag_type="text">therapy have shown good anti-HIV activity in vitro . How-</text>
<text top="298" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="9" tag_type="text">ever, not all of them have been tested in clinical trials. As</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="9" tag_type="text">reported in the literature, the trials conducted to date have</text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="9" tag_type="text">used a suicide gene (HyTK), transdominant negative pro-</text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="9" tag_type="text">teins (Rev M10, TdRev, or huM10), a chimeric receptor<i>in vitro </i></text>
<text top="343" left="55" width="241" height="13" font="font4" id="p1_t25" reading_order_no="22" segment_no="9" tag_type="text">(CD Î¶ ), an RNA decoy (RRE), and ribozymes (anti- tat / vpr<a href="">Rev [33,34</a>] and</text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="9" tag_type="text">ribozyme and tat ribozyme, RRz2). A trial using siRNA<a href=""> [35]. Ap</a>tamers can be used in con-</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="9" tag_type="text">was started recently and the results have not yet been pub-<a href="">es [35</a>].</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="9" tag_type="text">lished in literature. Following is an account of these clini-<i><b>Application of bench-side treatment strategies to bedside</b></i></text>
<text top="392" left="55" width="221" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="9" tag_type="text">cal trials and their results (see Table 1 for summary).</text>
<text top="416" left="55" width="181" height="9" font="font6" id="p1_t30" reading_order_no="27" segment_no="11" tag_type="title">Protein-based approaches used in the clinic<i>in vitro </i></text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="12" tag_type="text">In 1996, Riddell et al . published one of the earliest trials,</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="12" tag_type="text">involving the use of a suicide gene [16]. This study</text>
<text top="450" left="55" width="241" height="10" font="font4" id="p1_t33" reading_order_no="30" segment_no="12" tag_type="text">enrolled six HIV-seropositive patients. Autologous CD8 + T</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="12" tag_type="text">cells were genetically modified using a retrovirus-medi-<i>in vitro</i></text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="12" tag_type="text">ated gene transfer technique. The retrovirus, designated</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="12" tag_type="text">HyTK, comprised the hygromycin phosphotransferase</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="12" tag_type="text">gene (Hy) and the herpes virus thymidine kinase gene</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="12" tag_type="text">(TK) as a fusion gene under the control of the murine</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="12" tag_type="text">leukemia virus (MLV) long terminal repeat (LTR). Hygro-</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="12" tag_type="text">mycin was used to positively select for transduced autolo-</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="12" tag_type="text">gous cells in vitro prior to infusion into the patient.</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="12" tag_type="text">Ganciclovir could have been used, if necessary, to nega-</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="12" tag_type="text">tively select (kill) the transduced cells in the patient. In<i>tat</i></text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="12" tag_type="text">four increasing doses, researchers transfused autologous</text>
<text top="591" left="55" width="241" height="10" font="font4" id="p1_t45" reading_order_no="42" segment_no="12" tag_type="text">HyTK-transduced CD8 + cells at 14-day intervals. There<i>vpr</i></text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="12" tag_type="text">were no significant side effects. However, five of six</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="12" tag_type="text">patients developed a CTL response to the foreign protein<i>tat </i></text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="12" tag_type="text">and thus rejected the modified CD8 + cells, which cleared</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="12" tag_type="text">in response to each subsequent transfusion. The results of</text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="12" tag_type="text">this trial suggested other strategies that would make mod-</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="12" tag_type="text">ified cells less susceptible to the immune response and<a href="">1 for </a>summary).</text>
<text top="674" left="55" width="146" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="12" tag_type="text">thus inspired further research [16].<i><b>Protein-based approaches used in the clinic</b></i></text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="13" tag_type="text">In the same year, Woffendin et al . published the results of</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="13" tag_type="text">a pilot trial involving a transdominant negative protein<i>et al</i></text>
<text top="721" left="55" width="241" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="13" tag_type="text">approach [36]. For genetic modification of CD4 + T cells,</text>
<text top="87" left="313" width="241" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="3" tag_type="text">they used Rev M10 and a deletion mutant of Rev M10,<a href="">[16</a>]. This study</text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="3" tag_type="text">which showed no antiviral activity. Woffendin and col-</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="3" tag_type="text">leagues transduced the T cells using a non-viral vector and</text>
<text top="122" left="313" width="241" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="3" tag_type="text">showed that following transfusion, there was a preferen-</text>
<text top="133" left="313" width="241" height="10" font="font4" id="p1_t60" reading_order_no="57" segment_no="3" tag_type="text">tial survival of Rev M10 modified CD4 + T-cells, as com-</text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="3" tag_type="text">pared to cells that received the mutant. They also detected</text>
<text top="157" left="313" width="241" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="3" tag_type="text">Rev M10 until 2 months post-infusion. Though there was</text>
<text top="169" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="3" tag_type="text">increased survival of Rev M10-expressing cells, the overall</text>
<text top="181" left="313" width="210" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="3" tag_type="text">numbers of transduced cells were low in vivo [36].</text>
<text top="204" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="7" tag_type="text">Trying to improve upon this trial, they conducted another</text>
<text top="215" left="313" width="241" height="10" font="font4" id="p1_t66" reading_order_no="63" segment_no="7" tag_type="text">pilot study in which they transduced CD4 + cells with Rev</text>
<text top="228" left="313" width="241" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="7" tag_type="text">M10, but this time they used retroviral vectors instead of</text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="7" tag_type="text">a nonviral vector [37]. They detected Rev M10 for an aver-<i>in vitro </i></text>
<text top="251" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="7" tag_type="text">age of 6 months post-infusion. In addition, cells trans-</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="7" tag_type="text">duced with Rev M10 survived longer than those</text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="7" tag_type="text">transduced with the negative control vector. There were</text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="7" tag_type="text">no detectable immune responses to the 'foreign proteins'</text>
<text top="298" left="313" width="241" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="7" tag_type="text">(Rev M10 or MLV gp70 envelope protein). Though these</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="7" tag_type="text">studies with Rev M10 showed an improved efficacy of</text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="7" tag_type="text">gene delivery with a retroviral vector, there was no effect</text>
<text top="333" left="313" width="134" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="7" tag_type="text">on the patients' viral loads [37].</text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="10" tag_type="text">In 2002, Kang et al . published the results of another trial</text>
<text top="369" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="10" tag_type="text">that used a transdominant negative mutant Rev protein</text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="10" tag_type="text">(TdRev) [38]. This study had only two subjects. Both were</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="10" tag_type="text">HIV positive and had malignancies. One had leukemia</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t81" reading_order_no="78" segment_no="10" tag_type="text">and the other had refractory Hodgkin's lymphoma. Four-</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t82" reading_order_no="79" segment_no="10" tag_type="text">teen days prior to receiving gene therapy, the researchers</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t83" reading_order_no="80" segment_no="10" tag_type="text">stopped their cyclosporine and HAART medications. Six</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="10" tag_type="text">days prior to gene therapy, the patients received fludarab-<a href="">ch [16</a>].</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="10" tag_type="text">ine-cyclophosphamide containing regimen (non-myelo-</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="10" tag_type="text">ablative) for five days and then cyclosporine and HAART<i>et al</i></text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="10" tag_type="text">was restarted. Each patient had an HIV negative sibling</text>
<text top="486" left="313" width="241" height="9" font="font4" id="p1_t88" reading_order_no="85" segment_no="10" tag_type="text">who was an HLA-compatible donor for bone marrow</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="10" tag_type="text">cells. The donor underwent blood apheresis followed by<a href="">proach [36]. For</a> genetic modification of CD4</text>
<text top="509" left="313" width="241" height="10" font="font4" id="p1_t90" reading_order_no="87" segment_no="10" tag_type="text">isolation of CD34 + cells. The cells were genetically modi-</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="10" tag_type="text">fied by using either TdRev or a control vector encoding</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="10" tag_type="text">human GP91phox. Following transplantation with these</text>
<text top="544" left="313" width="241" height="10" font="font4" id="p1_t93" reading_order_no="90" segment_no="10" tag_type="text">modified CD34 + syngeneic cells, the patients developed</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t94" reading_order_no="91" segment_no="10" tag_type="text">CMV antigenemia, which was treated. By day 96 post-</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t95" reading_order_no="92" segment_no="10" tag_type="text">transplantation, both patients showed 100% transfer of</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t96" reading_order_no="93" segment_no="10" tag_type="text">either gene into lymphoid and myeloid lineages. Both</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t97" reading_order_no="94" segment_no="10" tag_type="text">patients developed acute graft versus host reaction beyond</text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t98" reading_order_no="95" segment_no="10" tag_type="text">day 100, which was successfully treated. The patient with</text>
<text top="615" left="313" width="241" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="10" tag_type="text">Hodgkin's disease died 12 months after transplantation</text>
<text top="627" left="313" width="241" height="9" font="font4" id="p1_t100" reading_order_no="97" segment_no="10" tag_type="text">due to relapse of the disease unrelated to any complica-</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t101" reading_order_no="98" segment_no="10" tag_type="text">tion of the gene therapy [38]. In a follow-up paper pub-</text>
<text top="651" left="313" width="241" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="10" tag_type="text">lished by the same group, the second patient showed</text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t103" reading_order_no="100" segment_no="10" tag_type="text">persistence of TdRev at three years post-treatment and<i>in vivo </i></text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t104" reading_order_no="101" segment_no="10" tag_type="text">continued to be in remission. However, this might be due<a href="">[36]</a>.</text>
<text top="686" left="313" width="207" height="9" font="font4" id="p1_t105" reading_order_no="102" segment_no="10" tag_type="text">to the effect of HAART and not TdRev alone [39].</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t106" reading_order_no="103" segment_no="14" tag_type="text">A 2005 study involving the transdominant negative pro-</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t107" reading_order_no="104" segment_no="14" tag_type="text">tein approach was focused on the pediatric age group of</text>
</page>
</pdf2xml>
